Armistice Capital’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Armistice Capital’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-700,000	Closed	-$1.5M	–	72
2017 Q1	$1.5M	Sell	700,000 -2,136,000	-75%	-$8.03M	0.31%	43
2016 Q4	$12.5M	Buy	2,836,000 +736,000	+35%	+$3.49M	2.96%	7
2016 Q3	$10.2M	Sell	2,100,000 -564,000	-21%	-$2.57M	3.27%	5
2016 Q2	$8.79M	Buy	+2,664,000	New	+$10.1M	3.35%	4

Other funds holding ARLZ

PCM

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CIM

Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return

Armistice Capital's ARLZ Position: Q2 2017 in Review

Armistice Capital sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2017, closing a stake of 700,000 shares — an estimated $1.5M sold.

Armistice Capital first reported a position in ARLZ in Q2 2016 and held it in 4 quarters. The position peaked at $12.5M in Q4 2016. 72 funds tracked by Wall St. Rank hold ARLZ as of Q2 2017.

Armistice Capital reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2017 after selling out during the quarter.
Armistice Capital sold 700,000 Aralez Pharmaceuticals Inc. shares in Q2 2017, an estimated $1.5M.
Armistice Capital first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 4 quarters.
Armistice Capital's Aralez Pharmaceuticals Inc. position peaked at $12.5M in Q4 2016.
72 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2017.

Based on Armistice Capital's 13F filing for Q2 2017, filed 14 Aug 2017.